Forty Seven lines up Roche as second partner for CD47 cancer immunotherapy – FierceBiotech
FierceBiotech |
Forty Seven lines up Roche as second partner for CD47 cancer immunotherapy
FierceBiotech Forty Seven has added Roche to its partner list for CD47-targeted immuno-oncology candidate, with Roche's Genentech unit agreeing to sponsor two trials of the antibody in combination with its PD-L1 inhibitor Tecentriq. It's the second I-O partnership … |
